Ignite Creation Date:
2024-10-26 @ 3:36 PM
Last Modification Date:
2024-10-26 @ 3:36 PM
Study NCT ID:
NCT06524024
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-07-16
Brief Title:
Clinical Study of Tumor Polypeptide DC-CTL in the Treatment of Solid Tumors
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Clinical Study of Tumor Polypeptide DC-CTL in the Treatment of Solid Tumors
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
DC-CTL
Brief Summary:
This clinical study is a real-world exploratory study to observe the safety and initial effectiveness of DC-CTL cells combined with conventional anti-tumor therapy in patients with colorectal cancer esophageal cancer lung cancer liver cancer breast cancer and other solid tumors
Detailed Description:
This clinical study is a real-world exploratory study to observe the safety and initial effectiveness of DC-CTL cells combined with conventional anti-tumor therapy in patients with colorectal cancer esophageal cancer lung cancer liver cancer breast cancer and other solid tumors In this study DC-CTL cells were injected once a day for two consecutive days 1-2 days after study participants received a conventional antitumor regimen and subcutaneous injections of DC cells were administered before a second infusion of DC-CTL cells A total of about 4-6 cycles of cell infusion are required and the specific number of infusion and the composition of the peptide pool are determined by the investigator based on clinical needs and test results After the cells have been transfused their safety is examined first and their effectiveness is evaluated during follow-up According to the needs this study plans to enroll about 20-200 patients with solid tumors such as colorectal cancer esophageal cancer lung cancer liver cancer and breast cancer If the disease progresses during treatment it is evaluated comprehensively by the investigator according to the clinical situation to determine whether the patient can be withdrawn from the study Study participants in the follow-up phase who develop disease progression begin other anti-tumor therapy without reaching disease progression after infusion and voluntarily request to withdraw from the follow-up phase will be withdrawn from the follow-up phase and will be followed for survival only
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None